Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications
K Nademanee,
R Kannan,
J Hendrickson,
M Ookhtens,
I Kay,
and
BN Singh
Administration of amiodarone (600 to 1,600 mg/day) to 28 patients during long-term digoxin therapy (0.25 +/- 0.05 mg/day) increased serum digoxin level from 0.97 +/- 0.45 to 1.98 +/- 0.84 ng/ml (p less than 0.001). Gastrointestinal side effects occurred in nine patients, central nervous system reactions occurred in five and cardiovascular reactions occurred in four. Pharmacokinetic studies in six patients with a 1 mg intravenous digoxin dose before and during amiodarone therapy increased serum digoxin level at 30 minutes from 8.59 +/- 1.68 to 10.07 +/- 1.70 ng/ml (p less than 0.05). Amiodarone caused a 31% prolongation of digoxin elimination half-life from 49.5 +/- 8.8 to 65.0 +/- 28.8 hours, but the increase in half-life was not statistically significant. Total body clearance was reduced significantly (29%, p less than 0.05) from 2.05 +/- 0.76 to 1.46 +/- 0.64 ml/min per kg. Nonrenal clearance also showed a significant decrease (33%, p less than 0.05) from 1.20 +/- 0.46 to 0.80 +/- 0.30 ml/min per kg. The renal clearance decreased by 22% and the volume of distribution decreased by 11% after amiodarone therapy, but these changes were not significant. The data show that the mechanism of digoxin-amiodarone interaction is multifactorial and emphasize the need for close monitoring of serum digoxin levels and clinical features during concurrent digoxin-amiodarone therapy.
This article has been cited by other articles:
|
|
|
|
 
E. Kimoto, J. Chupka, Y. Xiao, Y.-a. Bi, and D. B. Duignan
Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes
Drug Metab. Dispos.,
January 1, 2011;
39(1):
47 - 53.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dorian
Clinical Pharmacology of Dronedarone: Implications for the Therapy of Atrial Fibrillation
Journal of Cardiovascular Pharmacology and Therapeutics,
December 1, 2010;
15(4_suppl):
15S - 18S.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner
A Salute to Our Founding Editor-in-Chief Bramah N. Singh, MD, DPhil, DSc, FRCP
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
154 - 156.
[PDF]
|
|
|
|
|
|
|
S. de Denus and S. A. Spinler
Optimal Digoxin Concentrations for Patients With Heart Failure
JAMA,
May 28, 2003;
289(20):
2643 - 2643.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tanaka, K. Matsumoto, K. Ueno, M. Kodama, K. Yoneda, Y. Katayama, and K. Miyatake
Effect of Clarithromycin on Steady-State Digoxin Concentrations
Ann. Pharmacother.,
February 1, 2003;
37(2):
178 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden
Inhibition of P-Glycoprotein Mediated Drug Transport : A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine
Circulation,
February 2, 1999;
99(4):
552 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-G. Li and S. H. Hohnloser
Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1998;
3(2):
185 - 194.
[Abstract]
[PDF]
|
|
|
|
